Confirmed allergy to apatinin and or its excipients;
Hypertension (high blood pressure) that can not be controlled by drugs;
A history of active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery no older than 30 days;
NYHA III-IV heart function, or severe hepatic or renal insufficiency (Grade 4);
Presence of multiple factors that affect oral medications, such as difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction;
Pregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;
Patients who have a history of psychotropics abuse and can not quit, or who have mental disorders;
Participation in other drug clinical trial within the last 4 weeks;
Prior therapy with VEGFR inhibitors such as sorafenib and sunitinib;
Presence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;
Patients who can not tolerate apatinib treatment as judged by the investigator depending on the their medical history;
Patients that are considered ineligible for this study by the investigator.

NCT03475589_exc_T1
Condition
allergy
NCT03475589_exc_T2
Drug
apatinin
NCT03475589_exc_T3
Drug
excipients
NCT03475589_exc_T4
Scope
apatinin and or its excipients
NCT03475589_exc_T5
Condition
Hypertension
NCT03475589_exc_T6
Condition
high blood pressure
NCT03475589_exc_T7
Qualifier
controlled by drugs
NCT03475589_exc_T8
Drug
drugs
NCT03475589_exc_T9
Negation
not
NCT03475589_exc_T10
Qualifier
active
NCT03475589_exc_T11
Condition
hemorragge
NCT03475589_exc_T12
Condition
ulcer
NCT03475589_exc_T13
Condition
intestinal perforation
NCT03475589_exc_T14
Condition
intestinal obstruction
NCT03475589_exc_T15
Condition
major surgery
NCT03475589_exc_T16
Temporal
no older than 30 days
NCT03475589_exc_T17
Scope
active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery
NCT03475589_exc_T18
Measurement
NYHA
NCT03475589_exc_T19
Value
III-IV
NCT03475589_exc_T20
Condition
heart function
NCT03475589_exc_T21
Qualifier
severe
NCT03475589_exc_T22
Condition
atic or ufficiency (G
NCT03475589_exc_T23
Condition
renal insufficiency
NCT03475589_exc_T24
Qualifier
Grade 4
NCT03475589_exc_T25
Scope
hepatic or renal insufficiency
NCT03475589_exc_T26
Observation
factors that affect oral medications
NCT03475589_exc_T27
Condition
difficulty swallowing
NCT03475589_exc_T28
Condition
nausea
NCT03475589_exc_T29
Condition
vomiting
NCT03475589_exc_T30
Condition
chronic diarrhea
NCT03475589_exc_T31
Condition
intestinal obstruction
NCT03475589_exc_T32
Scope
difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction
NCT03475589_exc_T34
Observation
history
NCT03475589_exc_T35
Condition
abuse
NCT03475589_exc_T36
Drug
psychotropics
NCT03475589_exc_T37
Condition
mental disorders
NCT03475589_exc_T40
Drug
VEGFR inhibitors
NCT03475589_exc_T41
Drug
sorafenib
NCT03475589_exc_T42
Drug
sunitinib
NCT03475589_exc_T43
Scope
sorafenib and sunitinib
NCT03475589_exc_T45
Condition
tolerate
NCT03475589_exc_T46
Negation
not
NCT03475589_exc_T47
Drug
apatinib